In8Bio (INAB) Cash from Operations (2020 - 2026)
In8Bio (INAB) posted Cash from Operations of 4947000.0 for Q1 2026, down 131.28% sequentially from 2139000.0 in Q4 2025, and down 58.46% YoY from 11907890.52 in Q1 2025.
In8Bio (INAB) Cash from Operations (2020 - 2026) Analysis & Trends
In8Bio has reported Cash from Operations for 7 years, with the latest figure at 4947000.0 in Q1 2026.
- Quarterly Cash from Operations fell 58.46% year-over-year to 4947000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14537000.0 (up 24.88% YoY) and the FY2025 annual result came in at 12712000.0, up 47.36% from the prior year.
- Cash from Operations declined to 4947000.0 in Q1 2026 per INAB's latest filing, from 2139000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2139000.0 in Q4 2025 and troughed at 7949000.0 in Q4 2022.
- A 5-year average of 5251117.65 and a median of 5338000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 265.3% in 2022, then jumped 60.58% in 2025.
- Over 5 years, Cash from Operations stood at 7949000.0 in 2022, then soared by 38.99% to 4850000.0 in 2023, then increased by 16.95% to 4028000.0 in 2024, then surged by 46.9% to 2139000.0 in 2025, then sank by 131.28% to 4947000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 4947000.0, 2139000.0, and 3524000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | -3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.75 Mn |
| Jun 30, 2026 | -3.75 Mn |
| Mar 31, 2026 | -4.95 Mn |
| Mar 31, 2026 | -4.95 Mn |
| Dec 31, 2025 | -2.14 Mn |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | -3.52 Mn |
| Sep 30, 2025 | -3.52 Mn |
| Jun 30, 2025 | -3.93 Mn |
| Jun 30, 2025 | -3.93 Mn |
| Mar 31, 2025 | -3.12 Mn |
| Mar 31, 2025 | -3.12 Mn |
| Dec 31, 2024 | -4.03 Mn |
| Dec 31, 2024 | -4.03 Mn |
| Sep 30, 2024 | -6.11 Mn |
| Sep 30, 2024 | -6.11 Mn |
| Jun 30, 2024 | -6.09 Mn |
| Jun 30, 2024 | -6.09 Mn |
| Mar 31, 2024 | -7.92 Mn |
| Mar 31, 2024 | -7.92 Mn |